Anavex Life Sciences Corp (AVXL)

[falconer66a]

Next, What Gets Reported, And What Happens?

Right now, except for the very few who scrutinize the information on this message board and the listings in the CTAD program, no one else in the general public knows that Anavex will be presenting, revealing top line data from their big, long placebo-controlled clinical study of blarcamesine tested on people with early-stage Alzheimer’s.

It will be interesting to see how the media react and write about Anavex’s short presentation. Before that, Anavex very likely will post details of the clinical results. How will those data and findings be presented in the news media? “Anavex Drug Shows Great Promise for Alzheimer’s.” Or, “New Alzheimer’s Drug With Unknown Chemistry Will Need New Studies.”

From the start (now, many years ago) I’ve always contended that real success for Anavex Life Sciences Corp won’t occur until the news media accurately convey to lay audiences both a) the very positive clinical outcomes from blarcamesine, and b) that those clinical results occurred absent any obviating or serious side effects. When those perspectives are laid out in the general news media (starting with defining articles in The New York Times), a diagnosis of Alzheimer’s will no longer be popularly (and accurately) regarded as the death sentence it is. The focus will be no longer on inventing or using some monoclonal antibody that digests beta-amyloid agglomerations or tau tangles; it will be on “When can we get this blarcamesine!?”